Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 Jan 1;99(1):97–105. doi: 10.1172/JCI119139

Effects of recombinant human growth hormone on muscle protein turnover in malnourished hemodialysis patients.

G Garibotto 1, A Barreca 1, R Russo 1, A Sofia 1, P Araghi 1, A Cesarone 1, M Malaspina 1, F Fiorini 1, F Minuto 1, A Tizianello 1
PMCID: PMC507772  PMID: 9011582

Abstract

To assess the effect of recombinant human growth hormone (rhGH) on muscle protein metabolism in uremic patients with malnutrition, forearm [3H]phenylalanine kinetics were evaluated in six chronically wasted (body weight 79% of ideal weight) hemodialysis (HD) patients in a self-controlled, crossover study. Forearm protein dynamics were evaluated before, after a 6-wk course of rhGH (5 mg thrice weekly) and after a 6-wk washout period. After rhGH: (a) forearm phenylalanine net balance--the difference between phenylalanine incorporation into and phenylalanine release from muscle proteins--decreased by 46% (-8+/-2 vs. -15+/-2 nmol/min x 100 ml at the baseline and -11+/-2 after washout, P < 0.02); (b) phenylalanine rate of disposal, an index of protein synthesis, increased by 25% (25+/-5 vs. 20+/-5 at the baseline and 20+/-4 after washout, P < 0.03); (c) phenylalanine rate of appearance, an index of protein degradation, was unchanged (33+/-5 vs. 35+/-5 at the baseline and 31+/-4 after washout); (d) forearm potassium release declined (0.24+/-0.13 vs. 0.60+/-0.15 microeq/min at the baseline, and 0.42+/-0.20 microeq/min after washout P < 0.03); (e) changes in the insulin-like growth factor binding protein (IGFBP)-1 levels and insulin-like growth factor-I (IGF-I)/IGFBP-3 ratios accounted for 15.1% and 47.1% of the percent variations in forearm net phenylalanine balance, respectively. Together, these two factors accounted for 62.2% of variations in forearm net phenylalanine balance during and after rhGH administration. These data indicate: (a) that rhGH administration in malnourished hemodialysis patients is followed by an increase in muscle protein synthesis and by a decrease in the negative muscle protein balance observed in the postabsorptive state; and (b) that the reduction in net protein catabolism obtained with rhGH can be accounted for by the associated changes in circulating free, but not total, IGF-I levels.

Full Text

The Full Text of this article is available as a PDF (203.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ANDRES R., BALTZAN M. A., CADER G., ZIERLER K. L. Effect of insulin on carbohydrate metabolism and on potassium in the forearm of man. J Clin Invest. 1962 Jan;41:108–115. doi: 10.1172/JCI104452. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Alexis S. D., Vilaire G., Young V. R. Cell-free studies of protein synthesis with skeletal muscle from normal and potassium-depleted rats. J Nutr. 1971 Feb;101(2):273–285. doi: 10.1093/jn/101.2.273. [DOI] [PubMed] [Google Scholar]
  3. Allon M., Dansby L., Shanklin N. Glucose modulation of the disposal of an acute potassium load in patients with end-stage renal disease. Am J Med. 1993 May;94(5):475–482. doi: 10.1016/0002-9343(93)90081-Y. [DOI] [PubMed] [Google Scholar]
  4. Allon M. Hyperkalemia in end-stage renal disease: mechanisms and management. J Am Soc Nephrol. 1995 Oct;6(4):1134–1142. doi: 10.1681/ASN.V641134. [DOI] [PubMed] [Google Scholar]
  5. Allon M., Takeshian A., Shanklin N. Effect of insulin-plus-glucose infusion with or without epinephrine on fasting hyperkalemia. Kidney Int. 1993 Jan;43(1):212–217. doi: 10.1038/ki.1993.34. [DOI] [PubMed] [Google Scholar]
  6. Bergström J. Nutrition and mortality in hemodialysis. J Am Soc Nephrol. 1995 Nov;6(5):1329–1341. doi: 10.1681/ASN.V651329. [DOI] [PubMed] [Google Scholar]
  7. Bonilla S., Goecke I. A., Bozzo S., Alvo M., Michea L., Marusic E. T. Effect of chronic renal failure on Na,K-ATPase alpha 1 and alpha 2 mRNA transcription in rat skeletal muscle. J Clin Invest. 1991 Dec;88(6):2137–2141. doi: 10.1172/JCI115544. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Borah M. F., Schoenfeld P. Y., Gotch F. A., Sargent J. A., Wolfsen M., Humphreys M. H. Nitrogen balance during intermittent dialysis therapy of uremia. Kidney Int. 1978 Nov;14(5):491–500. doi: 10.1038/ki.1978.154. [DOI] [PubMed] [Google Scholar]
  9. Brismar K., Fernqvist-Forbes E., Wahren J., Hall K. Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes. J Clin Endocrinol Metab. 1994 Sep;79(3):872–878. doi: 10.1210/jcem.79.3.7521354. [DOI] [PubMed] [Google Scholar]
  10. CANNON P. R., FRAZIER L. E., HUGHES R. H. Influence of potassium on tissue protein synthesis. Metabolism. 1952 Jan;1(1):49–57. [PubMed] [Google Scholar]
  11. Chan W., Valerie K. C., Chan J. C. Expression of insulin-like growth factor-1 in uremic rats: growth hormone resistance and nutritional intake. Kidney Int. 1993 Apr;43(4):790–795. doi: 10.1038/ki.1993.112. [DOI] [PubMed] [Google Scholar]
  12. Clowes G. H., Jr, Randall H. T., Cha C. J. Amino acid and energy metabolism in septic and traumatized patients. JPEN J Parenter Enteral Nutr. 1980 Mar-Apr;4(2):195–205. doi: 10.1177/014860718000400225. [DOI] [PubMed] [Google Scholar]
  13. Copeland K. C., Nair K. S. Acute growth hormone effects on amino acid and lipid metabolism. J Clin Endocrinol Metab. 1994 May;78(5):1040–1047. doi: 10.1210/jcem.78.5.8175957. [DOI] [PubMed] [Google Scholar]
  14. Daughaday W. H., Mariz I. K., Blethen S. L. Inhibition of access of bound somatomedin to membrane receptor and immunobinding sites: a comparison of radioreceptor and radioimmunoassay of somatomedin in native and acid-ethanol-extracted serum. J Clin Endocrinol Metab. 1980 Oct;51(4):781–788. doi: 10.1210/jcem-51-4-781. [DOI] [PubMed] [Google Scholar]
  15. Deferrari G., Garibotto G., Robaudo C., Canepa A., Bagnasco S., Tizianello A. Leg metabolism of amino acids and ammonia in patients with chronic renal failure. Clin Sci (Lond) 1985 Aug;69(2):143–151. doi: 10.1042/cs0690143. [DOI] [PubMed] [Google Scholar]
  16. Ding H., Gao X. L., Hirschberg R., Vadgama J. V., Kopple J. D. Impaired actions of insulin-like growth factor 1 on protein Synthesis and degradation in skeletal muscle of rats with chronic renal failure. Evidence for a postreceptor defect. J Clin Invest. 1996 Feb 15;97(4):1064–1075. doi: 10.1172/JCI118499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Fine R. N., Pyke-Grimm K., Nelson P. A., Boechat M. I., Lippe B. M., Yadin O., Kamil E. Recombinant human growth hormone treatment of children with chronic renal failure: long-term (1- to 3-year) outcome. Pediatr Nephrol. 1991 Jul;5(4):477–481. doi: 10.1007/BF01453685. [DOI] [PubMed] [Google Scholar]
  18. Fryburg D. A., Barrett E. J. Growth hormone acutely stimulates skeletal muscle but not whole-body protein synthesis in humans. Metabolism. 1993 Sep;42(9):1223–1227. doi: 10.1016/0026-0495(93)90285-v. [DOI] [PubMed] [Google Scholar]
  19. Fryburg D. A., Gelfand R. A., Barrett E. J. Growth hormone acutely stimulates forearm muscle protein synthesis in normal humans. Am J Physiol. 1991 Mar;260(3 Pt 1):E499–E504. doi: 10.1152/ajpendo.1991.260.3.E499. [DOI] [PubMed] [Google Scholar]
  20. Fryburg D. A. Insulin-like growth factor I exerts growth hormone- and insulin-like actions on human muscle protein metabolism. Am J Physiol. 1994 Aug;267(2 Pt 1):E331–E336. doi: 10.1152/ajpendo.1994.267.2.E331. [DOI] [PubMed] [Google Scholar]
  21. Fryburg D. A., Louard R. J., Gerow K. E., Gelfand R. A., Barrett E. J. Growth hormone stimulates skeletal muscle protein synthesis and antagonizes insulin's antiproteolytic action in humans. Diabetes. 1992 Apr;41(4):424–429. doi: 10.2337/diab.41.4.424. [DOI] [PubMed] [Google Scholar]
  22. Garibotto G., Russo R., Sofia A., Sala M. R., Robaudo C., Moscatelli P., Deferrari G., Tizianello A. Skeletal muscle protein synthesis and degradation in patients with chronic renal failure. Kidney Int. 1994 May;45(5):1432–1439. doi: 10.1038/ki.1994.187. [DOI] [PubMed] [Google Scholar]
  23. Gelfand R. A., Barrett E. J. Effect of physiologic hyperinsulinemia on skeletal muscle protein synthesis and breakdown in man. J Clin Invest. 1987 Jul;80(1):1–6. doi: 10.1172/JCI113033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Goecke I. A., Bonilla S., Marusic E. T., Alvo M. Enhanced insulin sensitivity in extrarenal potassium handling in uremic rats. Kidney Int. 1991 Jan;39(1):39–43. doi: 10.1038/ki.1991.5. [DOI] [PubMed] [Google Scholar]
  25. Guarnieri G., Toigo G., Situlin R., Faccini L., Coli U., Landini S., Bazzato G., Dardi F., Campanacci L. Muscle biopsy studies in chronically uremic patients: evidence for malnutrition. Kidney Int Suppl. 1983 Dec;16:S187–S193. [PubMed] [Google Scholar]
  26. Haffner D., Schaefer F., Girard J., Ritz E., Mehls O. Metabolic clearance of recombinant human growth hormone in health and chronic renal failure. J Clin Invest. 1994 Mar;93(3):1163–1171. doi: 10.1172/JCI117069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Hokken-Koelega A. C., Stijnen T., de Muinck Keizer-Schrama S. M., Wit J. M., Wolff E. D., de Jong M. C., Donckerwolcke R. A., Abbad N. C., Bot A., Blum W. F. Placebo-controlled, double-blind, cross-over trial of growth hormone treatment in prepubertal children with chronic renal failure. Lancet. 1991 Sep 7;338(8767):585–590. doi: 10.1016/0140-6736(91)90604-n. [DOI] [PubMed] [Google Scholar]
  28. Horber F. F., Haymond M. W. Human growth hormone prevents the protein catabolic side effects of prednisone in humans. J Clin Invest. 1990 Jul;86(1):265–272. doi: 10.1172/JCI114694. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Ikizler T. A., Wingard R. L., Breyer J. A., Schulman G., Parker R. A., Hakim R. M. Short-term effects of recombinant human growth hormone in CAPD patients. Kidney Int. 1994 Oct;46(4):1178–1183. doi: 10.1038/ki.1994.382. [DOI] [PubMed] [Google Scholar]
  30. Kopple J. D., Ding H., Gao X. L. Altered physiology and action of insulin-like growth factor 1 in skeletal muscle in chronic renal failure. Am J Kidney Dis. 1995 Jul;26(1):248–255. doi: 10.1016/0272-6386(95)90180-9. [DOI] [PubMed] [Google Scholar]
  31. Kopple J. D. The rationale for the use of growth hormone or insulin-like growth factor I in adult patients with renal failure. Miner Electrolyte Metab. 1992;18(2-5):269–275. [PubMed] [Google Scholar]
  32. Krieg R. J., Jr, Santos F., Chan J. C. Growth hormone, insulin-like growth factor and the kidney. Kidney Int. 1995 Aug;48(2):321–336. doi: 10.1038/ki.1995.300. [DOI] [PubMed] [Google Scholar]
  33. Laager R., Ninnis R., Keller U. Comparison of the effects of recombinant human insulin-like growth factor-I and insulin on glucose and leucine kinetics in humans. J Clin Invest. 1993 Oct;92(4):1903–1909. doi: 10.1172/JCI116783. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Lee P. D., Conover C. A., Powell D. R. Regulation and function of insulin-like growth factor-binding protein-1. Proc Soc Exp Biol Med. 1993 Oct;204(1):4–29. doi: 10.3181/00379727-204-43630. [DOI] [PubMed] [Google Scholar]
  35. Lim V. S., Bier D. M., Flanigan M. J., Sum-Ping S. T. The effect of hemodialysis on protein metabolism. A leucine kinetic study. J Clin Invest. 1993 Jun;91(6):2429–2436. doi: 10.1172/JCI116477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Louard R. J., Fryburg D. A., Gelfand R. A., Barrett E. J. Insulin sensitivity of protein and glucose metabolism in human forearm skeletal muscle. J Clin Invest. 1992 Dec;90(6):2348–2354. doi: 10.1172/JCI116124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Manson J. M., Wilmore D. W. Positive nitrogen balance with human growth hormone and hypocaloric intravenous feeding. Surgery. 1986 Aug;100(2):188–197. [PubMed] [Google Scholar]
  38. Mauras N., Beaufrere B. Recombinant human insulin-like growth factor-I enhances whole body protein anabolism and significantly diminishes the protein catabolic effects of prednisone in humans without a diabetogenic effect. J Clin Endocrinol Metab. 1995 Mar;80(3):869–874. doi: 10.1210/jcem.80.3.7533772. [DOI] [PubMed] [Google Scholar]
  39. Phillips L. S., Fusco A. C., Unterman T. G., del Greco F. Somatomedin inhibitor in uremia. J Clin Endocrinol Metab. 1984 Oct;59(4):764–772. doi: 10.1210/jcem-59-4-764. [DOI] [PubMed] [Google Scholar]
  40. Price S. R., England B. K., Bailey J. L., Van Vreede K., Mitch W. E. Acidosis and glucocorticoids concomitantly increase ubiquitin and proteasome subunit mRNAs in rat muscle. Am J Physiol. 1994 Oct;267(4 Pt 1):C955–C960. doi: 10.1152/ajpcell.1994.267.4.C955. [DOI] [PubMed] [Google Scholar]
  41. Reaich D., Price S. R., England B. K., Mitch W. E. Mechanisms causing muscle loss in chronic renal failure. Am J Kidney Dis. 1995 Jul;26(1):242–247. doi: 10.1016/0272-6386(95)90179-5. [DOI] [PubMed] [Google Scholar]
  42. Salomon F., Cuneo R. C., Hesp R., Sönksen P. H. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med. 1989 Dec 28;321(26):1797–1803. doi: 10.1056/NEJM198912283212605. [DOI] [PubMed] [Google Scholar]
  43. Schulman G., Wingard R. L., Hutchison R. L., Lawrence P., Hakim R. M. The effects of recombinant human growth hormone and intradialytic parenteral nutrition in malnourished hemodialysis patients. Am J Kidney Dis. 1993 May;21(5):527–534. doi: 10.1016/s0272-6386(12)80399-4. [DOI] [PubMed] [Google Scholar]
  44. Thissen J. P., Ketelslegers J. M., Underwood L. E. Nutritional regulation of the insulin-like growth factors. Endocr Rev. 1994 Feb;15(1):80–101. doi: 10.1210/edrv-15-1-80. [DOI] [PubMed] [Google Scholar]
  45. Tizianello A., De Ferrari G., Garibotto G., Gurreri G., Robaudo C. Renal metabolism of amino acids and ammonia in subjects with normal renal function and in patients with chronic renal insufficiency. J Clin Invest. 1980 May;65(5):1162–1173. doi: 10.1172/JCI109771. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Tönshoff B., Edén S., Weiser E., Carlsson B., Robinson I. C., Blum W. F., Mehls O. Reduced hepatic growth hormone (GH) receptor gene expression and increased plasma GH binding protein in experimental uremia. Kidney Int. 1994 Apr;45(4):1085–1092. doi: 10.1038/ki.1994.145. [DOI] [PubMed] [Google Scholar]
  47. Valk N. K., vd Lely A. J., de Herder W. W., Lindemans J., Lamberts S. W. The effects of human growth hormone (GH) administration in GH-deficient adults: a 20-day metabolic ward study. J Clin Endocrinol Metab. 1994 Oct;79(4):1070–1076. doi: 10.1210/jcem.79.4.7525625. [DOI] [PubMed] [Google Scholar]
  48. Welbourne T., Joshi S., McVie R. Growth hormone effects on hepatic glutamate handling in vivo. Am J Physiol. 1989 Dec;257(6 Pt 1):E959–E962. doi: 10.1152/ajpendo.1989.257.6.E959. [DOI] [PubMed] [Google Scholar]
  49. Yki-Järvinen H., Young A. A., Lamkin C., Foley J. E. Kinetics of glucose disposal in whole body and across the forearm in man. J Clin Invest. 1987 Jun;79(6):1713–1719. doi: 10.1172/JCI113011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. ZIERLER K. L., RABINOWITZ D. ROLES OF INSULIN AND GROWTH HORMONE, BASED ON STUDIES OF FOREARM METABOLISM IN MAN. Medicine (Baltimore) 1963 Nov;42:385–402. doi: 10.1097/00005792-196311000-00002. [DOI] [PubMed] [Google Scholar]
  51. Ziegler T. R., Lazarus J. M., Young L. S., Hakim R., Wilmore D. W. Effects of recombinant human growth hormone in adults receiving maintenance hemodialysis. J Am Soc Nephrol. 1991 Dec;2(6):1130–1135. doi: 10.1681/ASN.V261130. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES